FDA-approved indications for tirzepatide-based weight management (Zepbound) require BMI ≥30 OR BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
Compounded tirzepatide eligibility is determined by the licensed prescriber and may follow the same BMI thresholds or use clinical judgment for patients with related metabolic conditions. The legitimate medical use of compounded tirzepatide should follow analogous clinical criteria — it should not be prescribed for cosmetic purposes in patients with normal weight. Always discuss eligibility with a licensed clinician.
NexLife is structured around clinical best practices for tirzepatide. The same flat-rate pricing applies across the entire titration schedule ($186/mo on the 12-month plan from 2.5 mg through 15 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000